Olumacostat glasaretil

Drug Profile

Olumacostat glasaretil

Alternative Names: DRM 01; DRM-01B; VAL-001

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT
  • Developer Dermira
  • Class Antiacnes; Furans; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 05 Mar 2018 Adverse events and efficacy data from the two Phase III pivotal trials (CLAREOS-1 and CLAREOS-2) in Acne vulgaris (In adolescents, In children, In adults), which did not met its co-primary endpoints, released by Dermira
  • 21 Dec 2017 Dermira completes the phase III CLAREOS-1 trial for Acne vulgaris (In Children, in adolescents, in adults, in elderly) in USA, Australia and Canada (Topical) (NCT03073486)
  • 28 Nov 2017 Dermira completes the phase III CLAREOS-2 trial for Acne vulgaris (In Children, in adolescents, in adults, in elderly) in USA, Australia and Canada (Topical) (NCT03028363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top